In addition, the PI3K-Akt signaling pathway might be the main pathway for SMB to inhibit ovarian cancer because the significant genes HSP90AA1, CDK2, and PIK3CG in this pathway receive the action of multiple ingredients in SMB. This evidence concerns the gene HSP90AA1 and ovarian carcinoma.